No profile data available.
NeoGenomics, Inc. (NEO) is a healthcare company in the medical testing laboratories industry, based in Fort Myers, United States, with about 2,200 full-time employees.
It reported revenue of $727.33 million for fiscal year 2025, up 10.1% from fiscal year 2024, and net income of -$108.03 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $201.66 million, up 11.2% from a year before. Its market capitalization was $1.57 billion as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
NeoGenomics reported $727.33 million in revenue for fiscal year 2025, up 10.1% from $660.57 million in fiscal year 2024. In Q2 2026 revenue was $201.66 million.
$1.57 billion as of December 4, 2025.
Listed companies of a similar size in the same industry (medical testing laboratories) include Quest Diagnostics Incorporated (DGX), Labcorp Holdings Inc. (LH), GeneDx Holdings Corp. (WGS), Opko Health, Inc. (OPK).